A novel antibody combination to identify KIR2DS2high natural killer cells in KIR2DL3/L2/S2 heterozygous donors. (2019)
Attributed to:
Using MHC class I peptides to modulate NK cell activity, as a basis for immunotherapy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/tan.13413
PubMed Identifier: 30381896
Publication URI: http://europepmc.org/abstract/MED/30381896
Type: Journal Article/Review
Volume: 93
Parent Publication: HLA
Issue: 1
ISSN: 2059-2302